Investor Presentaiton
Cell-Based Immunotherapy Landscape
Company
Lead Indication
TC
BIOPHARM
Pre-Clinical
Phase 1/2
Phase 2/3
Status / Upcoming Milestone
TC
*
AML
BIOPHARM
> Adicet Bio
IN&bio
LAVA
THERAPEUTICS
**
NHL
1b/2a
2b
1b/2a
HAEM & CNS
1b/2a
Lung Cancer
1b/2a
KIROMIC
Solid Tumors
Phase 1
0.000
0000
0000
000000
ImCheck
therapeutics
Solid Tumors
1b/2a
Phase 2a complete
Commenced Phase 2b into pivotal (AML)
Plan to file Investigational New Drug Application (IND)
for ADI-925 in H2 2023 and ADI-270 in H1 2024
Plans to complete INB-200 Phase 1 study enrollment in
2023 with updated data expected later this year.
Expects to report additional safety and efficacy
data for the dose escalation phase of the trial in
the next twelve months,
FDA Authorization of IND to Initiate Phase 1
Clinical Trial of Deltacel
Achieved Primary Objective of Phase 1 Trial
* Formulation GMP of product in-house ** Formulation with contract development and manufacture organization
15View entire presentation